JP2018538367A5 - - Google Patents

Download PDF

Info

Publication number
JP2018538367A5
JP2018538367A5 JP2018545568A JP2018545568A JP2018538367A5 JP 2018538367 A5 JP2018538367 A5 JP 2018538367A5 JP 2018545568 A JP2018545568 A JP 2018545568A JP 2018545568 A JP2018545568 A JP 2018545568A JP 2018538367 A5 JP2018538367 A5 JP 2018538367A5
Authority
JP
Japan
Prior art keywords
medicament according
treatment
heart failure
medicament
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018545568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538367A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/063036 external-priority patent/WO2017091496A1/en
Publication of JP2018538367A publication Critical patent/JP2018538367A/ja
Publication of JP2018538367A5 publication Critical patent/JP2018538367A5/ja
Withdrawn legal-status Critical Current

Links

JP2018545568A 2015-11-24 2016-11-21 ホルミルペプチド受容体2/リポキシンa4受容体(fpr2/alx)の心臓疾患を治療するための標的設定 Withdrawn JP2018538367A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562259498P 2015-11-24 2015-11-24
US62/259,498 2015-11-24
PCT/US2016/063036 WO2017091496A1 (en) 2015-11-24 2016-11-21 Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease

Publications (2)

Publication Number Publication Date
JP2018538367A JP2018538367A (ja) 2018-12-27
JP2018538367A5 true JP2018538367A5 (enExample) 2019-12-19

Family

ID=57544530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018545568A Withdrawn JP2018538367A (ja) 2015-11-24 2016-11-21 ホルミルペプチド受容体2/リポキシンa4受容体(fpr2/alx)の心臓疾患を治療するための標的設定

Country Status (13)

Country Link
US (1) US20180325869A1 (enExample)
EP (1) EP3380091A1 (enExample)
JP (1) JP2018538367A (enExample)
KR (1) KR20180081528A (enExample)
CN (1) CN108348479A (enExample)
AU (1) AU2016359463A1 (enExample)
BR (1) BR112018010155A8 (enExample)
CA (1) CA3006291A1 (enExample)
EA (1) EA201891007A1 (enExample)
IL (1) IL259468A (enExample)
MX (1) MX2018005756A (enExample)
SG (1) SG11201803816RA (enExample)
WO (1) WO2017091496A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3414227B1 (en) 2015-12-10 2021-11-24 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102623473B1 (ko) 2017-06-09 2024-01-09 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
WO2018227067A1 (en) 2017-06-09 2018-12-13 Bristol-Myers Squibb Company Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
CN110997653B (zh) 2017-06-09 2023-06-06 百时美施贵宝公司 芳基杂环哌啶酮甲酰肽2受体和甲酰肽1受体激动剂
US11008301B2 (en) 2017-06-09 2021-05-18 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor agonists
US10676431B2 (en) 2018-03-05 2020-06-09 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
CN113166134B (zh) 2018-11-26 2024-06-14 百时美施贵宝公司 作为甲酰肽2受体激动剂的吡咯烷酮衍生物
IL299680A (en) 2020-07-09 2023-03-01 Bristol Myers Squibb Co Pyrazolone formyl peptide 2 receptor agonists
JP7802765B2 (ja) 2020-08-12 2026-01-20 ブリストル-マイヤーズ スクイブ カンパニー オキソピロリジン尿素fpr2アゴニスト

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2492167C2 (ru) * 2007-12-18 2013-09-10 Актелион Фармасьютиклз Лтд Производные аминотриазола в качестве агонистов alх
KR101905927B1 (ko) * 2010-11-17 2018-10-08 이도르시아 파마슈티컬스 리미티드 가교된 스피로[2.4]헵탄 에스테르 유도체
CA2871334A1 (en) * 2012-05-16 2013-11-21 Actelion Pharmaceuticals Ltd 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
EP3414227B1 (en) * 2015-12-10 2021-11-24 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
US10676431B2 (en) * 2018-03-05 2020-06-09 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists

Similar Documents

Publication Publication Date Title
JP2018538367A5 (enExample)
JP2020523327A5 (enExample)
CN110036005A (zh) 酰胺衍生物及其在药物中的应用
MX2024010140A (es) Nuevos metodos.
JP2016518337A5 (enExample)
JP2016510326A5 (enExample)
JP2015083580A5 (enExample)
JP2015508749A5 (enExample)
JP2018184433A5 (enExample)
JP2010530001A5 (enExample)
JP2014062126A5 (enExample)
JP2018537507A5 (enExample)
JP2017532343A5 (enExample)
JP2017222722A5 (enExample)
JP2021529829A5 (enExample)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
FI3562487T3 (fi) Metalloentsyymi-inhibiittoriyhdisteitä
JOP20220058A1 (ar) بروتينات اندماج علاجية
JP2016539157A5 (enExample)
MX389330B (es) Metodo de tratamiento de afecciones relacionadas con el receptor pgi2.
JP2015516419A5 (enExample)
JP2013087119A5 (enExample)
JP2018513846A5 (enExample)
JP2019518052A5 (enExample)
EP4477223A4 (en) A pharmaceutical composition comprising allopurinol, febuxostat, or a pharmaceutically acceptable salt, combined for the prevention or treatment of chronic nephropathy in a patient with elevated blood uric acid levels.